Millions of Medicare enrollees will gain their first-ever coverage for drugs for weight loss under a temporary pilot program that launches July 1. The program, called Medicare GLP-1 Bridge, will cover certain medications, including Wegovy and Zepbound, for eligible enrollees.

Who is Eligible?

Only certain Medicare enrollees are eligible for the program. To qualify, enrollees must be enrolled in a Part D drug coverage plan and meet specific health criteria, including a body mass index (BMI) of 35 or more, or a BMI between 30 and 35 with certain health conditions.

Eligible enrollees will pay $50 for a month’s supply of the medication, which is a steep discount compared to the cash-pay prices. The program is part of a deal between the Trump administration and drugmakers Eli Lilly and Novo Nordisk to reduce the cost of their anti-obesity medications.

What Medications are Covered?

The pilot program covers Wegovy tablets and injections, Zepbound KwikPens, and Foundayo tablets. The medications can be obtained through pharmacies, and eligible enrollees interested in Zepbound and Foundayo can also go to LillyDirect Pharmacy, the drugmaker’s direct-to-consumer website.

Original reporting: KTBS 3 (Shreveport) — read the source article.